Finland· FI-REL-REL299
Meningovax A+C
A meningokokken a, c, bivalent, gereinigtes polysaccharid-antigen product containing neisseria meningitidis group a polysaccharide + neisseria meningitidis group c polysaccharide, registered in Finland by Sanofi Pasteur MSD.
Checked against Fimea (Finland) on
Informational only — not a medical device.
The record
At a glance
Fimea (Finland)- Active substance
- Neisseria meningitidis group A polysaccharide + Neisseria meningitidis group C polysaccharide
- Manufacturer
- Sanofi Pasteur MSD
- Country
- Finland (FI)
- ATC code
- J07AH03
- ATC class
- Meningokokken A, C, bivalent, gereinigtes Polysaccharid-Antigen
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/eb51a324-57af-41f7-b758-309bb44321bc GET /v1/drugs/eb51a324-57af-41f7-b758-309bb44321bc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "injektiokuiva-aine ja liuotin, liuosta varten",
"route": null,
"ddd_unit": null,
"strength": null,
"atc_label": "meningokokkipolysakkaridi A, C, bivalentti",
"ma_number": "11739",
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": null,
"fimea_rel_id": "REL299",
"authorised_at": "1995-03-20"
}See everything about meningokokken a, c, bivalent, gereinigtes polysaccharid-antigen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.